Literature DB >> 18072171

Death temporally related to the use of a Beta adrenergic receptor antagonist in cocaine associated myocardial infarction.

Fareed N Fareed1, Gar Chan, Robert S Hoffman.   

Abstract

INTRODUCTION: Although it is commonly stated that the use of beta adrenergic receptor antagonists is contraindicated in patients with cocaine toxicity, actual clinical evidence of harm is lacking. This case helps to highlight the risks of beta adrenergic receptor antagonists in patients with chest pain associated with cocaine use. CASE REPORT: A 54-year-old man was brought to the emergency department (ED) complaining of chest pain after using approximately 1 gram of intranasal cocaine. Aspirin and nitroglycerin spray relieved his pain. Although he remained pain free, tachycardia persisted despite 15 mg of diazepam intravenously. Nearly two hours after presentation, a total of 5 mg of metoprolol was given for persistent tachycardia (115/minute) and an elevated troponin. Shortly thereafter, the patient complained of crushing substernal chest pain, developed pulseless electrical activity, and could not be resuscitated. DISCUSSION: The administration of beta adrenergic receptor antagonists exacerbates cocaine-induced lethality in animals. In humans given smaller doses of cocaine, beta adrenergic receptor antagonists exacerbate coronary vasoconstriction. Both effects are presumed to occur through unopposed alpha adrenergic receptor agonism. Despite these data, actual cases describing adverse effects in cocaine users given beta adrenergic receptor antagonists are uncommon. This case supports the potential lethality of a cocaine-beta adrenergic receptor antagonist interaction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18072171      PMCID: PMC3550023          DOI: 10.1007/bf03160934

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  20 in total

1.  TOX-ACLS: toxicologic-oriented advanced cardiac life support.

Authors:  T E Albertson; A Dawson; F de Latorre; R S Hoffman; J E Hollander; A Jaeger; W R Kerns; T G Martin; M P Ross
Journal:  Ann Emerg Med       Date:  2001-04       Impact factor: 5.721

2.  Cocaine use and acute coronary syndromes.

Authors:  K Blaho; S Winbery; L Park; H W Gresham
Journal:  Lancet       Date:  2001-10-20       Impact factor: 79.321

3.  Cardiovascular complications of cocaine use.

Authors:  R A Lange; L D Hillis
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

4.  Propranolol: a specific antagonist to cocaine.

Authors:  R T Rappolt; G R Gay; D S Inaba
Journal:  Clin Toxicol       Date:  1977       Impact factor: 4.467

5.  Propranolo in cocaine toxicity.

Authors:  R T Rappolt; G Gay; D S Inaba; N R Rappolt
Journal:  Lancet       Date:  1976-09-18       Impact factor: 79.321

6.  Acute cocaine intoxication in the conscious dog: studies on the mechanism of lethality.

Authors:  J D Catravas; I W Waters
Journal:  J Pharmacol Exp Ther       Date:  1981-05       Impact factor: 4.030

7.  Antagonism of intravenous cocaine lethality in nonhuman primates.

Authors:  M M Guinn; J A Bedford; M C Wilson
Journal:  Clin Toxicol       Date:  1980-06       Impact factor: 4.467

8.  Comparison of cerebrovascular effects of intravenous cocaine injection in fetal, newborn, and adult sheep.

Authors:  R Robinson; H Iida; T P O'Brien; M A Pane; R J Traystman; C A Gleason
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-07       Impact factor: 4.733

9.  Propranolol blocks cocaine-induced cerebral vasodilation in newborn sheep.

Authors:  T P O'Brien; M A Pane; R J Traystman; C A Gleason
Journal:  Crit Care Med       Date:  1999-04       Impact factor: 7.598

10.  Use of Inderal (propranolol-Ayerst) in I-a (early stimulative) and I-b (advanced stimulative) classification of cocaine and other sympathomimetic reactions.

Authors:  R T Rappolt; G Gay; D S Inaba; N Rappolt; R T Rappolt
Journal:  Clin Toxicol       Date:  1978       Impact factor: 4.467

View more
  4 in total

Review 1.  Treatment of patients with cocaine-induced arrhythmias: bringing the bench to the bedside.

Authors:  Robert S Hoffman
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

2.  Amelioration of the cardiovascular effects of cocaine in rhesus monkeys by a long-acting mutant form of cocaine esterase.

Authors:  Gregory T Collins; Kathy A Carey; Diwahar Narasimhan; Joseph Nichols; Aaron A Berlin; Nicholas W Lukacs; Roger K Sunahara; James H Woods; Mei-Chuan Ko
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

3.  Early use of beta blockers in patients with cocaine associated chest pain.

Authors:  Christian Espana Schmidt; Luciano Pastori; Gerald Pekler; Ferdinand Visco; Savi Mushiyev
Journal:  Int J Cardiol Heart Vasc       Date:  2015-06-14

4.  Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use.

Authors:  Rohan Sharma; Nidhi Kapoor; Kaustubh Suresh Chaudhari; Robert Hal Scofield
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.